Appili therapeutics reports fiscal year 2024 financial and operational results

Likmez™ (ati-1501) for metronidazole oral suspension 500mg/5ml launched and commercial sales ongoing funding commitments from u.s. air force academy intended to advance ati-1701 toward an ind submission to the fda engaging regulatory authorities to align on ati-1801 development plans  halifax, nova scotia, june 25, 2024 (globe newswire) -- appili therapeutics inc. (tsx:apli; otcpink: aplif) (the “company” or “appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended march 31, 2024 (“fye 2024”), and provided an update on the company's strategy for fiscal 2025. all figures are stated in canadian dollars unless otherwise stated.
ATI Ratings Summary
ATI Quant Ranking